The DNMBP knockout HAP1 polyclonal cells are a CRISPR/Cas9-mediated gene-disrupted cell population designed for loss-of-function studies of the DNMBP gene in a human near-haploid background. This polyclonal knockout model preserves the heterogeneity typical of a non-clonal population while ensuring robust target-gene disruption, enabling functional interrogation of DNMBP in a near?native cellular context. The product is derived from the HAP1 cell line and is intended for applications in cell biology, signal transduction, and disease modeling. By ablating DNMBP expression, researchers can explore its role in actin cytoskeleton regulation, membrane trafficking, and cell junction dynamics without the confounding influence of a second wild-type allele. The polyclonal format balances knockout efficiency with population-level experimental relevance.
The HAP1 cell line is a near-haploid human cell line originally established from a patient with chronic myelogenous leukemia (CML) in blast crisis. Its near-haploid karyotype, with a single copy of most chromosomes, simplifies genetic manipulation and reduces functional redundancy, making it a powerful platform for CRISPR knockout screens and functional genomics research. HAP1 cells retain key signaling pathways found in diploid human cells, yet the reduced genomic complexity facilitates unambiguous genotype?Cphenotype correlations. This cell line has been widely adopted for high-throughput knockout studies, drug target discovery, and mechanistic investigations where clonal heterogeneity is controlled. In the context of DNMBP knockout, the HAP1 background provides a clean system to examine the consequences of DNMBP loss without compensatory effects from a second allele, enhancing the interpretability of phenotypic assays.
DNMBP (also known as Tuba) is a scaffold protein and Cdc42-specific guanine nucleotide exchange factor (GEF) that plays a central role in coupling membrane dynamics to actin cytoskeleton remodeling. It is activated downstream of cell-cell adhesion receptors, integrins, and growth factor receptors such as EGFR. Upon activation, DNMBP locally activates Cdc42, which then engages downstream effectors including PAK kinases and the WASP/WAVE complex, leading to actin polymerization via the Arp2/3 complex. DNMBP also directly binds dynamin, cortactin, and SH3 domain-containing adaptors (Grb2, Nck), positioning it at the intersection of endocytosis, filopodia formation, and tight/adherens junction assembly. Through these interactions, DNMBP coordinates membrane fission with de novo actin filament nucleation, ensuring proper vesicle trafficking, cell shape changes, and intercellular junction integrity. Disruption of DNMBP uncouples these processes, offering a model to dissect the molecular choreography of Cdc42-mediated actin regulation.
In the HAP1 near-haploid background, DNMBP knockout generates a unique loss-of-function model that highlights the protein??s contributions to endocytic trafficking, actin reorganization, and cell junction maintenance. The absence of a second allele eliminates residual wild-type activity, enabling clear detection of phenotypic changes. Given that DNMBP is genetically associated with Alzheimer??s disease and is implicated in cancer cell migration and invasion, this knockout system allows researchers to directly link DNMBP loss to altered Cdc42 activation kinetics, impaired transferrin uptake, and compromised junctional integrity. The HAP1 cell line??s amenability to high-content imaging and biochemical assays makes it an ideal host for interrogating DNMBP-dependent actin dynamics and membrane remodeling events. This model thus provides a controlled environment to validate DNMBP as a potential therapeutic target and to explore disease-relevant mechanisms.
These polyclonal knockout cells are suited for a wide range of functional assays, including transferrin uptake assays to quantify endocytosis, Cdc42 activation pull-downs to measure GTPase activity, immunofluorescence staining of actin and junction markers (e.g., F-actin, tight junction proteins), and transwell migration/invasion assays to evaluate cell motility. They can be employed in co?immunoprecipitation experiments to map DNMBP interaction networks, as well as in drug target validation studies for neurodegenerative and oncological applications. Researchers investigating Alzheimer??s disease pathology may use this model to assess how DNMBP loss affects amyloid-related pathways, while cancer biologists can probe its role in cell invasion. For further details on custom orders or technical support, please contact Ascent Research.
